Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833966 | 0.91 | MGLL (0.73) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19833983 | 0.91 | MGLL (0.81) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19834081 | 0.91 | MGLL (1.00) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19833739 | 0.90 | MGLL (0.82) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19833881 | 0.90 | MGLL (0.79) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19833807 | 0.90 | MGLL (0.71) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19847927 | 0.88 | MGLL (0.66) | MGLLHTR1AHTR1DHTR1B | |
| SCHEMBL19833736 | 0.87 | MGLL (0.89) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19833718 | 0.86 | MGLL (0.71) | MGLLHTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL19833777 | 0.86 | MGLL (0.73) | MGLLHTR1AHTR1DHTR1BNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | MAG, ACHE, HTT | MGLL 129/4885HTR1A 381/4885HTR1D 567/4885 |
| US-10106556-B2 | Heterocyclic compound | MAG, ACHE, HTT | MGLL 129/4885HTR1A 381/4885HTR1D 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.